一个向肝脏的基于糖原的纳米平台能够有效地静止CTGF并减轻肝纤维化
Min Gao1, Zhongtao Wen1, Xinyuan Zhang1
1Jiangnan University, 1800 Lihu Avenue, Binhu District, Wuxi, Jiangsu, Wuxi, 214122, CHINA.
Nanotechnology
|February 9, 2026
概括
一个新的纳米粒子系统有效地提供基因沉默疗法来治疗肝纤维化. 这种方法提高了慢性肝病管理的治疗疗效和生物安全性.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝纤维化是肝硬化的一种前兆,由于治疗选择有限,它带来了重大的临床挑战.
- 目前用于肝纤维化的基因沉默疗法在传递,稳定性和向方面面临障碍.
- 开发有效的传递系统对于推进基因沉默疗法至关重要.
研究的目的:
- 开发一个有针对性的纳米粒子系统,以有效地输送siRNA治疗肝纤维化.
- 设计一种生物相容和稳定的纳米载体,以提高基因沉默效率.
- 在肝纤维化的临床前模型中评估新系统的治疗潜力.
主要方法:
- 一个乳酸修饰的氨基化糖原 (Lac-AGly) 纳米粒子系统是使用天然糖原合成的.
- 这些纳米颗粒装载了向结合组织生长因子 (CTGF) 的siRNA,以创建Lac-AGly/siCTGF纳米复合体.
- 纳米粒子的表征包括形态,大小和泽塔潜力分析.
- 在体内研究评估了Lac-AGly/siCTGF在减轻肝纤维化的疗效.
主要成果:
- 拉克-AGly纳米粒子通过ASGPR.证明了有效的siRNA结合和选择性肝细胞向通过ASGPR.
- 拉克-AGly/siCTGF纳米复合体显示出均的球形形态 (247.2 ± 8.8 nm) 和正泽塔电位 (28.5 ± 3.8 mV).
- 在体内给药显著降低了肝纤维化,使原阳性区域从14.3%减少到3.1%.
- 该系统表现出改善的血清稳定性和有利的生物安全性.
结论:
- 拉克-AGly/siCTGF纳米粒子系统提供了一个有希望的,生物相容的,稳定的平台,用于向的siRNA输送.
- 这种新的策略显著提高了基因沉默的有效性,用于精确的分子干预肝纤维化.
- 开发的系统代表了一种可翻译的方法来管理慢性肝病和预防肝硬化.
相关概念视频
Transcription Attenuation in Prokaryotes
18.5K
Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure. Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
18.5K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
207
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
207
Cystic Fibrosis: Pathogenesis
895
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
895
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System
6.2K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.2K
Cystic Fibrosis: Management
549
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
549


